A phase III, randomized, double-blind, placebo-controlled, multiple dose study to assess the efficacy, safety and tolerability of RG1068 (synthetic human secretin) in children with autism and gastrointestinal dysfunction
Phase of Trial: Phase III
Latest Information Update: 18 Nov 2005
At a glance
- Drugs Secretin (Primary)
- Indications Autistic disorder
- Focus Therapeutic Use
- 09 Oct 2005 New trial record.